Clinical trialsCompany release

J&J's Tremfya beats placebo in Phase 4 STAR axial psoriatic arthritis study at Week 24

Johnson & Johnson EMEA · Fri 20 Nov 2026

Johnson & Johnson says guselkumab met primary and major secondary endpoints in biologic-naïve patients with MRI-confirmed axial involvement, including reduced sacroiliac joint inflammation.

Johnson & Johnson has reported Week-24 results from STAR, a Phase 4 study of Tremfya (guselkumab) in biologic-naïve adults with active psoriatic arthritis and MRI-confirmed axial involvement.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release: Johnson & Johnson EMEA ↗

Article written by VigiEye from the official source (Johnson & Johnson EMEA). Claims are the company's own. AI-assisted; check the source before acting.